- Galena Biopharma (GALE -6.4%) opens with a thud after Jim Cramer suggests investors take profits after shares more than tripled during the past three months.
- Cramer questioned CEO Dr. Mark Ahn about the history of failures for drugs similar to NeuVax, GALE's lead clinical candidate, saying he was skeptical about the drug's chances for approval.
- In response to criticisms, Ahn says "of the patients in the Phase II study of NeuVax, 0% of those patients had a recurrence of cancer."
From other sites
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
Video at CNBC.com (Jan 16, 2014)
at CNBC.com (Jan 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs